OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism.
Location: United States, California, Palo Alto
Employees: 1-10
Total raised: $62.3M
Founded date: 2021
Investors 1
| Date | Name | Website |
| 09.11.2023 | Longitude ... | longitudec... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.11.2023 | Series A | $60M | - |
| 02.11.2022 | Grant | $2.3M | - |
Mentions in press and media 2
| Date | Title | Description | Source |
| 07.11.2023 | OrsoBio Raises $60M Series A Financing | OrsoBio, a Menlo Park, CA-based clinical-stage biopharmaceutical company, raised $60M in Series A fu... | finsmes.co... |
| - | OrsoBio | “Developing first-in-class therapies to treat patients with metabolic disorders including diabetes, ... | fastfounde... |